You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 166 No. 7, April 10, 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Lipids and Lipid Disorders
 •Diabetes Mellitus
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Role of Fibrates in a Statin World

Arch Intern Med. 2006;166:715-716.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This issue of the ARCHIVES includes a focus on fibrates, with the publication of 2 articles, one an 18-year mortality follow-up report from the Helsinki Heart Study (HHS) and the other, a report on the role of bezafibrate in preventing the progression of insulin resistance.1-2 In an era dominated by statins (is there anything they cannot do?), it is timely to ask whatever became of the fibrates and what role, if any, they have in a statin world.

It all started with fibrates over 30 years ago. Clofibrate was the first agent to be tested in clinical trials in the 1970s designed to evaluate the effect of lowering cholesterol level on cardiac outcomes. Unfortunately, one of these trials (the World Health Organization's Cooperative Primary Prevention Trial) showed an excess risk of cancer and all-cause mortality among those receiving active treatment, and clofibrate has since been removed from the market. . . . [Full Text of this Article]


AUTHOR INFORMATION
Hanna E. Bloomfield, MD, MPH



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Attenuation of Progression of Insulin Resistance in Patients With Coronary Artery Disease by Bezafibrate
Alexander Tenenbaum, Enrique Z. Fisman, Valentina Boyko, Michal Benderly, David Tanne, Moti Haim, Zipora Matas, Michael Motro, and Solomon Behar
Arch Intern Med. 2006;166(7):737-741.
ABSTRACT | FULL TEXT  

Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study
Leena Tenkanen, Matti Mänttäri, Petri T. Kovanen, Hanna Virkkunen, and Vesa Manninen
Arch Intern Med. 2006;166(7):743-748.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs
Ali et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:706-711.
ABSTRACT | FULL TEXT  

Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
Peters
Clin. Diabetes 2008;26:3-7.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment
Sanossian et al.
Stroke 2007;38:1104-1109.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.